Menu Search
Equities

Akari Therapeutics PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
CLA:MUN

Akari Therapeutics PLC

Actions
  • Price (EUR)0.212
  • Today's Change0.016 / 8.16%
  • Shares traded--
  • 1 Year change-82.33%
  • Beta0.3005
Data delayed at least 15 minutes, as of Feb 10 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.

  • Revenue in USD (TTM)0.00
  • Net income in USD-15.77m
  • Incorporated2004
  • Employees8.00
  • Location
    Akari Therapeutics PLC401 EAST JACKSON STREET, SUITE 3300TAMPA 33602United StatesUSA
  • Phone+1 (929) 274-7510
  • Fax+1 (646) 843-9352
  • Websitehttps://www.akaritx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.